Fig. 2From: A phase II randomized trial of sodium oligomannate in Alzheimer’s dementiaFull analysis set of the primary efficacy outcome of ADAS-cog12 change scores from baseline to week 24 among the three groups. p values were derived upon comparison of changes from week 24 to baseline with the placebo groupBack to article page